Firm News

Home 9 News Item 9 Wiggin and Dana advises BioArctic AB in Option, Collaboration and License Agreement with Novartis Pharma AG

Wiggin and Dana advises BioArctic AB in Option, Collaboration and License Agreement with Novartis Pharma AG

August 28, 2025

Wiggin and Dana represented BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) in connection with its option, collaboration, and license agreement with Novartis Pharma AG, combining BioArcticโ€™s proprietary BrainTransporterโ„ข technology with a Novartis proprietary antibody directed to an undisclosed target in neurodegeneration. Under the agreement, BioArctic will receive a $30 million up-front payment, and if Novartis exercises their option, BioArctic will be eligible to receive additional payments of up to $772 million plus tiered mid-single digit royalties.

The Wiggin deal team consisted of Toby Bannon, Patti Melick, and David Devich.

To learn more and read the official press release, please click here.

 

 

Resources

Firm Highlights